<< Health Dialog's Care Transitions and telephonic health coaching support reduces costs for Medicare beneficiaries | Blue Care Network reaches milestone: Enrolls 100,000 members for Healthy Blue Living >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | العربية | Nederlands | Ελληνικά | Русский | Svenska | Polski

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Published on September 14, 2009 at 12:28 PM · No Comments

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today the initiation of a second study, in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs. This study, led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University, is designed to build on the recently completed study that demonstrated the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation, and determine the most effective duration of delivery for treatment after exposure.

AEOL 10150 has been shown to be safe and well tolerated in two phase 1 safety studies, and in animal studies it has been proven to be efficacious in protecting the lungs from radiation damage and increasing survival at doses in the range of 5 to 30 mg/kg given daily up to 24 hrs after irradiation and administered for as long as 10 weeks. The compound mitigated functional lung injury in rats and led to a statistically significant survival advantage in mice. In rodents and humans, radiation of the lungs can cause reduced breathing capacity, pneumonitis, fibrosis, weight loss and death and is characterized by oxidative stress, inflammation and elevated macrophage counts. AEOL 10150 has proven to be an effective countermeasure to radiation exposure of the lungs in mice and rats.

“This study will provide important insight into the most appropriate length of treatment with AEOL 10150 to protect the lungs following exposure to radiation,” stated John L. McManus, President and Chief Executive Officer of Aeolus Pharmaceuticals, Inc. “The results of this study will be critical in helping us design the pivotal study in mice, which we expect will be one of the two species necessary for approval of AEOL 10150 as a countermeasure to nuclear threats under the US FDA’s Animal Rule.”

www.aeoluspharma.com

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading